•Molecular Therapeutics Division (MTD) Development of novel targeted therapies for clinical unmet needs in niche biomedical market
•Advanced Technology Center (ADT) Developing nanoscale, organic, inorganic and hybrid materials; commercializing the technologies for various applications
•Life Science Research Center (LSC) Developing novel active transdermal technology for the delivery of therapeutics and vaccines
New Anti-fibrosis Drug with Molecular Targeting DDS Completed Phase-1a Dose Escalation
Founded in 1918, Nitto Denko Corporation is Japan's leading diversified materials manufacturer offering over 13,000 high-value-added products to the global market. Nitto Denko's strength lies in its flexibility to add diverse functionalities to sheets, films and other materials, fully utilizing its core technologies such as polymer synthesis, adhesion and coating. The Nitto Denko group's wide spectrum of specialities include optical films for liquid crystal displays, automotive materials, reverse osmosis membranes for seawater desalination, transdermal drug delivery systems, and much more.
Nitto Denko Corporation is traded on the Tokyo Stock Exchange (TSE). Total net sales in fiscal year 2012 amounted to JP¥676 billion. Globally, Nitto Denko Corporation consists of 107 subsidiaries and employs over 30,000 people (as of March 2013).
Rewritable Holographic 3D Display
NDT has been engaged in the development of photorefractive materials from the viewpoint of developing novel, rewritable recording materials. The research company particularly focused on organic polymer-based materials which are inexpensive to produce and at the same time easy to coat on glass and plastic media. In 2002, NDT produced a photorefractive material and the associated system demonstrating an excellent compositional stability, while at the same time exhibiting the highest image strength and writing speed to date.
News 
Market Data 
Discover 
